Drug Shortage Report for TEVA-BUPROPION XL
| Report ID | 68577 |
| Drug Identification Number | 02439662 |
| Brand name | ACT BUPROPION XL |
| Common or Proper name | BUPROPION XL |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | BUPROPION HYDROCHLORIDE |
| Strength(s) | 300MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Packaging size | 500 |
| ATC code | N06AX |
| ATC description | ANTIDEPRESSANTS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | |
| Actual start date | 2018-12-01 |
| Estimated end date | 2020-02-29 |
| Actual end date | 2020-02-12 |
| Shortage status | Resolved |
| Updated date | 2020-02-13 |
| Company comments | Allocating inventory to support regular demand. Cannot support increased demand for this molecule, as well as now delays in releases from the mfg site. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v30 | 2020-02-13 | French | Compare |
| v29 | 2020-02-13 | English | Compare |
| v28 | 2020-01-17 | French | Compare |
| v27 | 2020-01-17 | English | Compare |
| v26 | 2019-12-19 | French | Compare |
| v25 | 2019-12-19 | English | Compare |
| v24 | 2019-12-12 | French | Compare |
| v23 | 2019-12-12 | English | Compare |
| v22 | 2019-12-05 | French | Compare |
| v21 | 2019-12-05 | English | Compare |
| v20 | 2019-10-03 | French | Compare |
| v19 | 2019-10-03 | English | Compare |
| v18 | 2019-09-19 | French | Compare |
| v17 | 2019-09-19 | English | Compare |
| v16 | 2019-09-10 | French | Compare |
| v15 | 2019-09-10 | English | Compare |
| v14 | 2019-09-10 | French | Compare |
| v13 | 2019-09-10 | English | Compare |
| v12 | 2019-09-10 | French | Compare |
| v11 | 2019-09-10 | English | Compare |